Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.
Paradkar MS, Pradhan NN, Balaji S, Gaikwad SN, Chavan A, Dharmashale SN, Sahasrabudhe T, Lokhande R, Deshmukh SA, Barthwal M, Atre S, Raskar SS, Sawant TU, Gupte AN, Kakrani A, Golub J, Padmapriyadarsini C, Gupta A, Gupte NA, Mave V. Paradkar MS, et al. Among authors: kakrani a. Ann Am Thorac Soc. 2023 Dec;20(12):1760-1768. doi: 10.1513/AnnalsATS.202302-144OC. Ann Am Thorac Soc. 2023. PMID: 38038600
Association of human leukocyte antigen class I and class II alleles and haplotypes in COVID-19 infection in a western Indian population.
Tripathy AS, Wagh P, Vishwakarma S, Akolkar K, Tripathy S, Jali P, Kakrani AL, Barthwal M, Gurav Y, Kadgi N, Nakate L, Abraham P. Tripathy AS, et al. Among authors: kakrani al. Infect Genet Evol. 2023 Sep;113:105468. doi: 10.1016/j.meegid.2023.105468. Epub 2023 Jun 16. Infect Genet Evol. 2023. PMID: 37331496 Free PMC article. No abstract available.
Correction: Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts.
Cox SR, Kadam A, Atre S, Gupte AN, Sohn H, Gupte N, Sawant T, Mhadeshwar V, Thompson R, Kendall E, Hofmann C, Suryavanshi N, Kerrigan D, Tripathy S, Kakrani A, Barthwal MS, Mave V, Golub JE; TB Aftermath study team. Cox SR, et al. Among authors: kakrani a. Trials. 2024 Mar 11;25(1):178. doi: 10.1186/s13063-024-07984-3. Trials. 2024. PMID: 38468342 Free PMC article. No abstract available.
T-cell responses in COVID-19 survivors 6-8 months after infection: A longitudinal cohort study in Pune.
Suryawanshi P, Patil-Takbhate B, Athavale P, Mirza S, Tripathy A, Kanitkar S, Shivnitwar S, Barthwal MS, Dole S, Chavan H, Jali P, Pawale S, Kakad D, Kakrani AL, Bhawalkar J, Gandhi M, Chaturvedi S, Karandikar M, Tripathy S. Suryawanshi P, et al. Among authors: kakrani al. Immun Inflamm Dis. 2024 Jun;12(6):e1238. doi: 10.1002/iid3.1238. Immun Inflamm Dis. 2024. PMID: 38860770 Free PMC article.
Lymphopenia with Altered T Cell Subsets in Hospitalized COVID-19 Patients in Pune, India.
Suryawanshi P, Takbhate B, Athavale P, Jali P, Memane N, Mirza S, Karandikar M, Kakrani AL, Kanitkar S, Gandham N, Barthwal MS, Dole S, Chaturvedi S, Pawale S, Tripathy A, Bhawalkar JS, Tripathy S. Suryawanshi P, et al. Among authors: kakrani al. Viral Immunol. 2023 Apr;36(3):163-175. doi: 10.1089/vim.2022.0123. Epub 2023 Mar 10. Viral Immunol. 2023. PMID: 36897333
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.
Kulkarni PS, Kadam A, Godbole S, Bhatt V, Raut A, Kohli S, Tripathi S, Kulkarni P, Ludam R, Prabhu M, Bavdekar A, Gogtay NJ, Meshram S, Kadhiravan T, Kar S, Narayana DHA, Samuel C, Kulkarni G, Gaidhane A, Sathyapalan D, Raut S, Hadda V, Bhalla HL, Bhamare C, Dharmadhikari A, Plested JS, Cloney-Clarke S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Gautam M, Gupta N, Panda S, Shaligram U, Poonawalla CS, Bhargava B, Gunale B, Kapse D; COVOVAX Study Group. Kulkarni PS, et al. Lancet Reg Health Southeast Asia. 2023 Mar;10:100139. doi: 10.1016/j.lansea.2022.100139. Epub 2023 Jan 11. Lancet Reg Health Southeast Asia. 2023. PMID: 36647543 Free PMC article.
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, Raut S, Kulkarni P, Apte A, Bavdekar A, Bhalla HL, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Pryor M, Hamilton S, Thakar M, Sannidhi RS, Baranwal P, Bhamare C, Dharmadhikari A, Gupta M, Poonawalla CS, Shaligram U, Kapse D; COVOVAX-Booster Study Group. Kulkarni PS, et al. Sci Rep. 2023 Oct 3;13(1):16579. doi: 10.1038/s41598-023-43578-w. Sci Rep. 2023. PMID: 37789040 Free PMC article. Clinical Trial.
Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.
Tripathy AS, Singh D, Trimbake D, Salwe S, Tripathy S, Kakrani A, Jali P, Chavan H, Yadav P, Sahay R, Sarje P, Babar P, Shete A, Nandapurkar A, Kulkarni M. Tripathy AS, et al. Among authors: kakrani a. Hum Vaccin Immunother. 2024 Dec 31;20(1):2410579. doi: 10.1080/21645515.2024.2410579. Epub 2024 Oct 21. Hum Vaccin Immunother. 2024. PMID: 39434214 Free PMC article.
64 results